ARFID Treatment Options: A Clinical Guide

ARFID is treatable. While the research base is still developing relative to other eating disorders — ARFID was only formally recognised in the DSM-5 in 2013 — there are now established, evidence-based treatment approaches that have demonstrated positive outcomes across age groups and presentations. This guide provides a comprehensive overview of the current treatment landscape, written for individuals with ARFID, their families, and the clinicians supporting them.

The Importance of Assessment Before Treatment

Because ARFID encompasses three distinct presentations — sensory-based avoidance, fear of aversive consequences, and low appetite — effective treatment begins with a thorough assessment that identifies which presentation or combination of presentations is driving the restriction. A treatment approach designed for fear-based ARFID will not be effective for someone whose primary driver is sensory sensitivity, and vice versa.

A comprehensive ARFID assessment typically includes:

• Medical evaluation: weight, height, growth trajectory (in children), nutritional status, blood work for common deficiencies (iron, zinc, calcium, vitamins B12 and D), and ruling out organic causes of food restriction (gastrointestinal conditions, food allergies, dysphagia)
• Nutritional assessment: dietary history, safe food inventory, supplement use, and assessment of nutritional adequacy
• Psychological evaluation: eating history, onset and course of restriction, fear hierarchy, sensory profile, comorbid conditions (anxiety, OCD, ASD, ADHD), and functional impairment
• Standardised measures: tools such as the Nine Item ARFID Screen (NIAS), the Pica, ARFID, and Rumination Disorder Interview (PARDI), or the ARFID Impact Scale may be used to quantify severity and guide treatment planning

The goal of assessment is not simply to confirm the diagnosis but to understand the specific mechanisms maintaining the restriction in this individual — which informs every subsequent treatment decision.

CBT-AR: The Leading Evidence-Based Treatment

Cognitive-Behavioural Therapy for Avoidant/Restrictive Food Intake Disorder (CBT-AR), developed by Dr Jennifer Thomas and Dr Kamryn Eddy at Massachusetts General Hospital and Harvard Medical School, is the most studied and most widely recommended psychological treatment for ARFID across the lifespan.¹

CBT-AR is explicitly modularised to address each of the three presentations separately. It is delivered in individual therapy format, typically over 20–30 sessions, and has been adapted for children (with parent involvement), adolescents, and adults.

Structure of CBT-AR

Phase 1: Psychoeducation and motivation. The therapist and patient develop a shared understanding of ARFID — its presentations, its mechanisms, and how it has affected the patient's life. Motivation for change is explored and strengthened. A personalised case formulation is developed.

Phase 2: Nutritional rehabilitation. Before food exposure begins, nutritional adequacy is addressed. This may involve introducing oral supplements, increasing portion sizes of safe foods, or working with a dietitian to ensure the patient has sufficient energy and nutrition to engage in the more challenging work ahead.

Phase 3: Presentation-specific treatment. This is the core of CBT-AR, and it differs depending on the primary presentation:

• Sensory module: Systematic food exposure using a hierarchy of foods ranked from least to most challenging. The patient works through the hierarchy gradually, with the therapist's support, building tolerance to new sensory properties.
• Fear module: Exposure and Response Prevention (ERP) targeting the specific feared consequences. Cognitive restructuring addresses catastrophic beliefs about eating outcomes. A graduated fear hierarchy is constructed and worked through.
• Low appetite module: Structured eating schedules, interoceptive awareness training, and motivational work to increase engagement with eating.

Phase 4: Relapse prevention. The final phase consolidates gains, addresses remaining challenges, and prepares the patient for continued progress after treatment ends.

Evidence Base

A 2021 prospective study by Thomas et al. was the first to evaluate CBT-AR in adults, demonstrating feasibility, acceptability, and proof-of-concept outcomes including increased dietary variety and reduced functional impairment.² Multiple case series and open trials have demonstrated positive outcomes in children and adolescents. Randomised controlled trials are ongoing.

Family-Based Treatment for ARFID (FBT-ARFID)

Family-Based Treatment (FBT), originally developed for adolescent anorexia nervosa, has been adapted for ARFID in children and younger adolescents. FBT-ARFID involves parents taking an active, central role in the re-feeding process — externalising the disorder (treating ARFID as something separate from the child), and gradually returning control over eating to the child as recovery progresses.³

FBT-ARFID is particularly appropriate when:

• The child is young (typically under 12)
• Nutritional status is significantly compromised
• The child has limited insight into the disorder or limited motivation for individual therapy
• The family is able and willing to commit to the intensive involvement required

Occupational Therapy with Feeding Specialisation

For sensory-based ARFID, occupational therapy (OT) with a feeding specialisation is a valuable component of treatment, particularly for children. Occupational therapists trained in sensory integration work systematically to desensitise the sensory system to new food properties through structured, non-pressured exposure — often using play-based approaches with younger children.

OT interventions may include:

• Sensory exploration of food properties without expectation of eating (touching, smelling, looking)
• Gradual introduction of new textures through food chaining
• Oral motor exercises to address hypersensitivity in the mouth and throat
• Environmental modifications to reduce sensory overwhelm at mealtimes

Dietitian-Led Nutritional Rehabilitation

A registered dietitian experienced in ARFID is an essential member of the treatment team, regardless of which psychological intervention is being used. The dietitian's role includes:

• Assessing nutritional status and identifying deficiencies
• Designing a nutritional plan that ensures adequacy within the current safe food repertoire
• Introducing calorie-dense options to support weight restoration where needed
• Guiding gradual food expansion using food chaining principles
• Monitoring growth and nutritional markers over time (particularly in children)
• Providing psychoeducation about nutrition without adding pressure around eating

The dietitian's approach must be explicitly non-pressured and ARFID-informed. A dietitian who uses standard "healthy eating" frameworks without understanding ARFID may inadvertently increase anxiety and worsen restriction.

Pharmacotherapy

There is currently no medication approved specifically for ARFID. However, pharmacotherapy may be used adjunctively to address comorbid conditions that are maintaining the restriction:

• SSRIs (selective serotonin reuptake inhibitors): May be used for comorbid anxiety disorders, OCD, or depression that are contributing to restriction. Evidence is limited and case-based.
• Mirtazapine: Has been used in some cases to stimulate appetite in the low-appetite presentation, with limited case report evidence.
• Cyproheptadine: An antihistamine with appetite-stimulating properties, sometimes used in younger children with the low-appetite presentation.

Pharmacotherapy should always be considered in the context of a comprehensive treatment plan and not used as a standalone intervention. The evidence base for medication in ARFID is currently insufficient to support strong recommendations, and prescribing decisions should be made by a clinician experienced in eating disorders.⁴

Hospitalisation and Higher Levels of Care

In cases of severe malnutrition, medical instability, or failure to progress in outpatient treatment, higher levels of care may be necessary:

• Partial hospitalisation programme (PHP): Intensive day treatment, typically 5–6 hours per day, with structured meals and therapeutic support
• Residential treatment: 24-hour care in a specialised eating disorder facility
• Medical hospitalisation: For acute medical stabilisation, including nasogastric (NG) tube feeding where oral intake is insufficient to sustain life

Hospitalisation should be considered when weight is critically low, there is significant medical compromise (electrolyte abnormalities, cardiac changes, growth failure in children), or when the patient is unable to maintain safety in a less intensive setting.⁴

The Multidisciplinary Team

Optimal ARFID treatment involves a coordinated multidisciplinary team. The composition of the team depends on the individual's age, presentation, and severity, but typically includes:

Finding a Provider

ARFID is a relatively new diagnosis and specialist providers are not yet widely available in all regions. Resources for finding ARFID-informed clinicians include:

• ARFID Awareness UK: arfidawarenessuk.co.uk
• National Eating Disorders Association (NEDA): nationaleatingdisorders.org (US)
• Beat Eating Disorders: beateatingdisorders.org.uk (UK)
• ARFID Awareness Australia: arfidawareness.com.au
• MGH Eating Disorders Clinical and Research Program (CBT-AR developers): massgeneral.org/psychiatry/eating-disorders

---

References

Footnotes

1. Thomas JJ, Eddy KT. (2019). Cognitive-Behavioral Therapy for Avoidant/Restrictive Food Intake Disorder. Cambridge University Press. ↩

2. Thomas JJ, Becker KR, Breithaupt L, et al. (2021). Cognitive-behavioral therapy for adults with ARFID. International Journal of Eating Disorders. doi:10.1002/eat.23560. ↩

3. Lock J, Le Grange D. (2015). Treatment Manual for Anorexia Nervosa: A Family-Based Approach (2nd ed.). Guilford Press. [Adapted for ARFID] ↩

4. Ramirez Z, Gunturu S. (2024). Avoidant Restrictive Food Intake Disorder. StatPearls. https://www.ncbi.nlm.nih.gov/books/NBK603710/ ↩ ↩²